Senior CDER Management Panel Could Facilitate Novel Therapy Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CDER Director Janet Woodcock is creating an executive-level forum to deliberate medical policies, including those needed to smooth drug reviews. She envisions stakeholder input on topics for discussion by the panel.
You may also be interested in...
CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues
FDA is seeking public input on cross-cutting policy issues to bring before the senior-level group, which is also facing the challenge of reviewing dozens of “breakthrough therapy” designation requests relevant to CDER-regulated products.
FDA’s Jenkins On “Progressive Approval”: Don’t Lower The Efficacy Bar
Office of New Drugs director says a “weight of the evidence” standard will not provide reasonable assurance of drug efficacy and safety.
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
The Office of Medical Policy now houses the Office of Prescription Drug Promotion (formerly DDMAC) and the newly created Office of Medical Policy Initiatives.